Therapeutic Use:

Indications for TYSABRI:

In moderately-to-severely active Crohn's disease: to induce and maintain clinical response and remission in adult patients with evidence of inflammation who have had inadequate response to or are intolerant to conventional therapy and TNF-α inhibitors.

Adult:

≥18yrs: Give by IV infusion over 1hr; monitor during and for 1hr post-infusion. 300mg every 4 weeks. Discontinue after 12 weeks of induction therapy if no therapeutic response, or if unable to taper off chronic concomitant steroids within 6 months of starting therapy. May continue with aminosalicylates.